Immutep Regains Compliance with Nasdaq Minimum Bid Price Requirement
Compliance followed an ADS ratio change undertaken to address the minimum bid price deficiency.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Immutep (NASDAQ: IMMP) has regained compliance with Nasdaq’s minimum bid price requirement, resolving the previously notified deficiency affecting its American Depositary Shares.
Nasdaq’s written notification, dated 12 October 2026, confirmed that the closing bid price was at least US$1.00 per ADS for 10 consecutive business days, from 28 September to 9 October 2026. The matter is now closed. To address the deficiency, Immutep changed its ADS ratio from one ADS representing 10 ordinary shares to one representing 200 ordinary shares, effective 28 September 2026. Its ordinary shares were unaffected and continue trading on the ASX as IMM; its ADSs continue trading on the Nasdaq Global Market as IMMP.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- Moderate pointNasdaq minimum bid price compliance regained; the deficiency matter is now closed.
Negative
- Minor pointADS ratio increased from 10 to 200 ordinary shares per ADS to address the listing deficiency.
Key Figures
- Minimum bid price threshold
- US$1.00 per ADS
- Nasdaq Listing Rule 5450(a)(1)
- Consecutive compliant trading days
- 10 business days
- Closing bid price was at or above the Nasdaq threshold
- ADS ratio change
- 1 ADS per 10 ordinary shares to 1 ADS per 200 ordinary shares
- Effective September 28, 2026
Historical Context
-
Company changed ADS ratio from 1:10 to 1:200 to address Nasdaq minimum-bid compliance.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
lag-3 medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
SYDNEY, AUSTRALIA, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announced that it has received written notification from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq"), dated 12 October 2026 (US Eastern Time), confirming that the Company has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5450(a)(1).
Nasdaq determined that the closing bid price of the Company's American Depositary Shares ("ADSs") was at or above US
As announced on 30 April 2026, Nasdaq notified the Company by letter dated 27 April 2026 that the closing bid price of its ADSs had been below US
The ADS ratio change did not affect the Company's ordinary shares, which continue to trade on the ASX under the code IMM. The Company's ADSs continue to trade on the Nasdaq Global Market under the symbol IMMP.
This announcement was authorised for release by the CEO of Immutep Limited.
About Immutep
Immutep is a late-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease. The Company is a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3’s ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit www.immutep.com.
Forward-Looking Statements
This press release contains forward-looking statements, including statements regarding anticipated clinical development, regulatory progress and potential benefits of the Company’s product candidates. These forward-looking statements are based on current expectations, estimates and projections, and involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from those expressed or implied in such statements.
Factors that could cause actual results to differ materially include risks associated with clinical trial outcomes, regulatory developments, and the Company’s ability to advance its product candidates.
Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this release. Immutep undertakes no obligation to update or revise such statements, except as required by applicable law.
Disclaimer
This announcement has been prepared for informational purposes only and does not constitute an offer to sell, or a solicitation of an offer to buy, securities in any jurisdiction.
Australian Investors/Media:
Eleanor Pearson, Sodali & Co.
+61 2 9066 4071; eleanor.pearson@sodali.com
US Investors/Media:
Matthew Beck, astr partners
+1 (917) 415-1750; matthew.beck@astrpartners.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How did Immutep (IMMP) regain Nasdaq minimum bid price compliance?
Immutep’s ADS closing bid price was at or above US$1.00 for 10 consecutive business days, from 28 September to 9 October 2026. Nasdaq confirmed compliance with Listing Rule 5450(a)(1) in a written notification dated 12 October 2026 and closed the matter.
What ADS ratio change did Immutep (IMMP) make to address its Nasdaq deficiency?
Immutep changed its ratio from one ADS representing 10 ordinary shares to one ADS representing 200 ordinary shares, effective 28 September 2026. The change did not affect its ordinary shares, which continue trading on the ASX under IMM.